Oncopharmpod
Adjuvant Pembrolizumab (NSCLC), Elacestrant, & Pirtobrutinib
- Author: Vários
- Narrator: Vários
- Publisher: Podcast
- Duration: 0:17:58
- More information
Informações:
Synopsis
First - despite what you'll hear - it is pirTobrutinib, not pirobrutinib. Second - lots of great information on the current state of targeted therapies in adjuvant NSCLC and on two exciting new drugs: elacestrant and pirtobrutinib.
